rezdiffra
(Resmetirom)Madrigal Pharmaceuticals, Inc.
Usage: REZDIFFRA is indicated for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) and moderate to advanced liver fibrosis (F2 to F3 stages), in combination with diet and exercise. Approval is based on improved NASH and fibrosis, pending further confirmatory trials. Not for use in decompensated cirrhosis.